Biography

Dr. Satani finished his academic training as a primary care physician in 2008 and obtained his Masters in Public Health from the University of Texas Health Science Center (UTHealth) at Houston in 2013. He completed his postdoctoral training at the Institute for stroke and cerebrovascular diseases in 2019 and currently works as an Instructor in the Department of Neurology at UTHealth. He has over 10 years of basic science, clinical and translational research in the field of neurology.

Dr. Satani has expertise in cellular therapy, neuroimmunology and drug discovery. He has a US patent on the novel small molecule inhibitors and his peer-reviewed publications feature in top-tier journals such as Nature, Nature Chemical Biology, Nature Communications, and Cancer Cell. His current areas of research revolve around understanding the molecular mechanisms involved in ischemic stroke after cellular therapy.

Education

Medical Degree (MBBS)
Smt. N.H.L. Municipal Medical College - Ahmedabad, Gujarat, India,
Masters in Public Health
University of Texas Health Science Center at Houston, School of Public Health - Houston, Texas

Areas of Interest

Clinical Interests

  • Ischemic Stroke
  • Vascular Dementia

Research Interests

  • Cellular therapy in ischemic stroke
  • Molecular mechanisms mediating Lung-Brain and Spleen-Brain crosstalk after stroke

Publications

Publication Information

  1. Satani N, Giridhar K, Cai C, Wewior N, Norris DD, Olson SD, Aronowski J, & Savitz SI. (2019). Aspirin in stroke patients modifies the immunomodulatory interactions of marrow stromal cells and monocytes. Brain Res, 1720, 146298. doi:10.1016/j.brainres.2019.06.017
  2. Satani N, Cai C, Giridhar K, McGhiey D, George S, Parsha K, Nghiem DM, Valenzuela KS, Riecke J, Vahidy FS, & Savitz SI. (2019). World-Wide Efficacy of Bone Marrow Derived Mesenchymal Stromal Cells in Preclinical Ischemic Stroke Models: Systematic Review and Meta-Analysis. Front Neurol, 10, 405. doi:10.3389/fneur.2019.00405
  3. Leonard PG*, Satani N*, Maxwell D, Lin YH, Hammoudi N, Peng Z, Pisaneschi F, Link TM, Lee GR, Sun D, Prasad BAB, Di Francesco ME, Czako B, Asara JM, Wang YA, Bornmann W, DePinho RA, & Muller FL. (2016). SF2312 is a natural phosphonate inhibitor of enolase. Nat Chem Biol, 12(12), 1053-1058. doi:10.1038/nchembio.2195
  4. Satani N, Lin YH, Hammoudi N, Raghavan S, Georgiou DK, & Muller FL. (2016). ENOblock Does Not Inhibit the Activity of the Glycolytic Enzyme Enolase. PLoS One, 11(12), e0168739. doi:10.1371/journal.pone.0168739
  5. Satani N, & Savitz SI. (2016). Is Immunomodulation a Principal Mechanism Underlying How Cell-Based Therapies Enhance Stroke Recovery? Neurotherapeutics, 13(4), 775-782. doi:10.1007/s13311-016-0468-9
  6. Parsha K*, Mir O*, Satani N*, Yang B, Guerrero W, Mei Z, Cai C, Chen PR, Gee A, Hanley PJ, Aronowski J, & Savitz SI. (2017). Mesenchymal stromal cell secretomes are modulated by suspension time, delivery vehicle, passage through catheter, and exposure to adjuvants. Cytotherapy, 19(1), 36-46. doi:10.1016/j.jcyt.2016.10.006
    *Co-First Author

Google Scholar Citations Profile: https://scholar.google.com/citations?user=sSa7bNMAAAAJ&hl=en